Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease

Journal of Neuroscience

Volumn 28, Issue 19, 2008, Pages 5007-5017

  Meilandt, William J ^a,b   Yu, Gui Qiu ^a   Chin, Jeannie ^a,b   Roberson, Erik D ^a,b   Palop, Jorge J ^a,b   Wu, Tiffany ^a   Scearce Levie, Kimberly ^a,b   Mucke, Lennart ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

Author keywords

Amyloid; Dentate gyrus; Enkephalin; Entorhinal cortex; Mu opioid receptor; Spatial memory

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ENKEPHALIN; METENKEPHALIN; AMYLOID BETA PROTEIN; MESSENGER RNA; PREPROENKEPHALIN; PROTEIN PRECURSOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CONTROLLED STUDY; DENTATE GYRUS; GENETIC MANIPULATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; AGED; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; ENTORHINAL CORTEX; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; NERVE CELL; NERVE TRACT; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TRANSGENIC MOUSE; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; DENTATE GYRUS; DISEASE MODELS, ANIMAL; ENKEPHALIN, METHIONINE; ENKEPHALINS; ENTORHINAL CORTEX; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONS; PROTEIN PRECURSORS; RNA, MESSENGER; UP-REGULATION;

EID: 44949184540     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0590-08.2008     Document Type: Article

References (88)

1. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47:867-872.
2. Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, Dado RJ, Loh HH, Law PY, Wessendorf MW, Elde R (1995) Distribution and targeting of a μ-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15:3328-3341.
3. Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG (2006) Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody. J Clin Invest 116:825-832.
4. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403.
5. Bodnar RJ, Klein GE (2005) Endogenous opiates and behavior: 2004. Peptides 26:2629-2711.
6. Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JW, Woods JH, Traynor JR (2000) Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, β-funaltrexamine, and β-chlornaltrexamine. J Pharmacol Exp Ther 294:933-940.
7. Canli T, Cook RG, Miczek KA (1990) Opiate antagonists enhance the working memory of rats in the radial maze. Pharmacol Biochem Behav 36:521-525.
8. Caudle RM, Wagner JJ, Chavkin C (1991) Endogenous opioids released from perforant path modulate norepinephrine actions and inhibitory postsynaptic potentials in guinea pig CA3 pyramidal cells. J Pharmacol Exp Ther 258:18-26.
9. Cheng I, Scearce-Levie K, Legleiter J, Palop J, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe K, Muchowski P, Mucke L (2007) Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282:23818-23828.
10. Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, Mucke L (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24:4692-4697.
11. Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25:9694-9703.
12. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114:1179-1187.
13. Decker MW, Introini-Collison IB, McGaugh JL (1989) Effects of naloxone on Morris water maze learning in the rat: Enhanced acquisition with pretraining but not posttraining administration. Psychobiology 17:270-275.
14. deIpolyi A, Fang S, Wang F, Mucke L (2008) Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 29:253-266.
15. De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, Annaert W, Van Broeckhoven C, De Strooper B (2001) Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability. Hum Mol Genet 10:1665-1671.
16. Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA (2004) Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 367:164-167.
17. Derrick BE, Rodriguez SB, Lieberman DN, Martinez Jr JL (1992) Muopioid receptors are associated with the induction of hippocampal mossy fiber long-term potentiation. J Pharmacol Exp Ther 263:725-733.
18. Diez M, Koistinaho J, Kahn K, Games D, Hökfelt T (2000) Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F β-amyloid precursor protein - initial observations. Neuroscience 100:259-286.
19. Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold KH, Hokfelt T (2003) Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing β-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis 14:579-594.
20. Ding YQ, Kaneko T, Nomura S, Mizuno N (1996) Immunohistochemical localization of μ-opioid receptors in the central nervous system of the rat. J Comp Neurol 367:375-402.
21. Do VH, Martinez CO, Martinez Jr JL, Derrick BE (2002) Long-term potentiation in direct perforant path projections to the hippocampal CA3 region in vivo. J Neurophysiol 87:669-678.
22. Drake CT, Milner TA (1999) μ opioid receptors are in somatodendritic and axonal compartments of GABAergic neurons in rat hippocampal formation. Brain Res 849:203-215.
23. Duka T, Wuster M, Schubert P, Stoiber R, Herz A (1981) Selective localization of different types of opiate receptors in hippocampus as revealed by in vitro autoradiography. Brain Res 205:181-186.
24. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112-2117.
25. Frischknecht HR, Siegfried B, Riggio G, Waser PG (1983) Inhibition of morphine-induced analgesia and locomotor activity in strains of mice: a comparison of long-acting opiate antagonists. Pharmacol Biochem Behav 19:939-944.
26. Gall C (1988) Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci 8:1852-1862.
27. Gall C, Brecha N, Karten HJ, Chang KJ (1981) Localization of enkephalin-like immunoreactivity to identified axonal and neuronal populations of the rat hippocampus. J Comp Neurol 198:335-350.
28. Gallagher M (1982) Naloxone enhancement of memory processes: effects of other opiate antagonists. Behav Neural Biol 35:375-382.
29. Gallagher M (1985) Effect of β-funaltrexamine on retention of passive-avoidance conditioning. Behav Neural Biol 44:499-502.
30. Gallagher M, King RA, Young NB (1983) Opiate antagonists improve spatial memory. Science 221:975-976.
31. Godsil BP, Stefanacci L, Fanselow MS (2005) Bright light suppresses hyperactivity induced by excitotoxic dorsal hippocampus lesions in the rat. Behav Neurosci 119:1339-1352.
32. Gomez-Isla T, Price JL, McKeel Jr DW, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16:4491-4500.
33. Hamilton DA, Rosenfelt CS, Whishaw IQ (2004) Sequential control of navigation by locale and taxon cues in the Morris water task. Behav Brain Res 154:385-397.
34. Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM (2004) Mutations in APP have independent effects on Aβ and CTFγ generation. Neurobiol Dis 17:205-218.
35. Hong JS, McGinty JF, Grimes L, Kanamatsu T, Obie J, Mitchell CL (1988) Seizure-induced alterations in the metabolism of hippocampal opioid peptides suggest opioid modulation of seizure-related behaviors. NIDA Res Monogr 82:48-66.
36. Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233.
37. Izquierdo I (1979) Effect of naloxone and morphine on various forms of memory in the rat: possible role of endogenous opiate mechanisms in memory consolidation. Psychopharmacology (Berl) 66:199-203.
38. Izquierdo I, Dias RD (1981) Retrograde amnesia caused by Met-, Leu- and des-Try-Met-enkephalin in the rat and its reversal by naloxone. Neurosci Lett 22:189-193.
39. Izquierdo I, Graudenz M (1980) Memory facilitation by naloxone is due to release of dopaminergic and β-adrenergic systems from tonic inhibition. Psychopharmacology 67:265-268.
40. Izquierdo I, Paiva AC, Elisabetsky E (1980) Post-training intraperitoneal administration of leu-enkephalin and β-endorphin causes retrograde amnesia for two different tasks in rats. Behav Neural Biol 28:246 -250.
41. Jansen KL, Faull RL, Dragunow M, Synek BL (1990) Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors - an autoradiographic study. Neuroscience 39:613-627.
42. Kalyuzhny AE, Wessendorf MW (1998) Relationship of μ- and δ-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits. J Comp Neurol 392:528-547.
43. 5-enkephalin and the level of dynorphin A in the rat hippocampus. J Neurosci 6:3094-3102.
44. Kergoat H, Kergoat MJ, Justino L, Chertkow H, Robillard A, Bergman H (2002) Visual retinocortical function in dementia of the Alzheimer type. Gerontology 48:197-203.
45. Kiyosawa M, Bosley TM, Chawluk J, Jamieson D, Schatz NJ, Savino PJ, Sergott RC, Reivich M, Alavi A (1989) Alzheimer's disease with prominent visual symptoms. Clinical and metabolic evaluation. Ophthalmology 96:1077-1085; discussion 1085-1086.
46. Kobayashi DT, Chen KS (2005) Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 4:173-196.
47. Kojima N, Wang J, Mansuy IM, Grant SGN, Mayford M, Kandel ER (1997) Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc Natl Acad Sci USA 94:4761-4765.
48. Kojima N, Ishibashi H, Obata K, Kandel ER (1998) Higher seizure susceptibility and enhanced tyrosine phosphorylation on N-methyl- D-aspartate receptor subunit 2B in fyn transgenic mice. Learn Mem 5:429-445.
49. Liu H, Gao HM, Zhang WQ, Tang YY, Song HS (2004) Effects of chronic administration of PL017 and β-funaltrexamine hydrochloride on susceptibility of kainic acid-induced seizures in rats. Sheng Li Xue Bao 56:101-106.
50. Lleó A, Greenberg SM, Growdon JH (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57:513-533.
51. Madison DV, Nicoll RA (1988) Enkephalin hyperpolarizes interneurones in the rat hippocampus. J Physiol (Lond) 398:123-130.
52. Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci 18:22-29.
53. Mapstone M, Steffenella TM, Duffy CJ (2003) A visuospatial variant of mild cognitive impairment: getting lost between aging and AD. Neurology 60:802-808.
54. Martinez Jr JL, Conner P, Dana RC (1985) Central versus peripheral actions of Leu-enkephalin on acquisition of a one-way active avoidance response in rats. Brain Res 327:37-43.
55. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM (2001) μ-, δ- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res 893:121-134.
56. McNamara RK, Skelton RW (1991) Pretraining morphine impairs acquisition and performance in the Morris water maze: motivation reduction rather than amnesia. Psychobiology 19:313-322.
57. Mendez MF, Cherrier MM (2003) Agnosia for scenes in topographagnosia. Neuropsychologia 41:1387-1395.
58. Messing RB, Jensen RA, Martinez Jr JL, Spiehler VR, Vasquez BJ, Soumireu-Mourat B, Liang KC, McGaugh JL (1979) Naloxone enhancement of memory. Behav Neural Biol 27:266-275.
59. Moneta ME, Höllt V (1990) Perforant path kindling induces differential alterations in the mRNA levels coding for prodynorphin and proenkephalin in the rat hippocampus. Neurosci Lett 110:273-278.
60. Morris BJ, Feasey KJ, Ten Bruggencate G, Herz A, Höllt V (1988) Electrical stimulation in vivo increases the expression of proenkephalin mRNA and decreases the expression of prodynorphin mRNA in rat hippocampal granule cells. Proc Natl Acad Sci USA 85:3226-3230.
61. 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
62. Nicoll RA, Alger BE, Jahr CE (1980) Enkephalin blocks inhibitory pathways in the vertebrate CNS. Nature 287:22-25.
63. Nieto MM, Guen SL, Kieffer BL, Roques BP, Noble F (2005) Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the Δ opioid receptors. Neuroscience 135:305-313.
64. O'Brien HL, Tetewsky SJ, Avery LM, Cushman LA, Makous W, Duffy CJ (2001) Visual mechanisms of spatial disorientation in Alzheimer's disease. Cereb Cortex 11:1083-1092.
65. Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L (2003) Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci USA 100:9572-9577.
66. Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu G-Q, Mucke L (2005) Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci 25:9686-9693.
67. Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768-773.
68. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55:697-711.
69. Pomara N, Roberts R, Rhiew HB, Stanley M, Gershon S (1985) Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease. Neurobiol Aging 6:233-236.
70. Reisberg B, Ferris SH, Anand R, Mir P, Geibel V, De Leon MJ, Roberts E (1983) Effects of naloxone in senile dementia: a double-blind trial. N Engl J Med 308:721-722.
71. Rinne JO, Lönnberg P, Marjamäki P, Mölsä P, Säkö E, Paljävi L (1993) Brain methionine- and leucine-enkephalin receptors in patients with dementia. Neurosci Lett 161:77-80.
72. Roberson ED, Mucke L (2006) 100 years and counting: prospects for defeating Alzheimer's disease. Science 314:781-784.
73. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L (2007) Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754.
74. Rockenstein EM, McConlogue L, Tan H, Gordon M, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer's disease. J Biol Chem 270:28257-28267.
75. Serby M, Resnick R, Jordan B, Adler J, Corwin J, Rotrosen JP (1986) Naltrexone and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10:587-590.
76. Simmons ML, Chavkin C (1996) Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol 39:145-196.
77. Snead III OC, Bearden LJ (1980) Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucine enkephalin. Science 210:1031-1033.
78. Stengaard-Pedersen K (1983) Comparative mapping of opioid receptors and enkephalin immunoreactive nerve terminals in the rat hippocampus. A radiohistochemical and immunocytochemical study. Histochemistry 79:311-333.
79. Stumm RK, Zhou C, Schulz S, Hollt V (2004) Neuronal types expressing μ and δ-opioid receptor mRNA in the rat hippocampal formation. J Comp Neurol 469:107-118.
80. h) currents. J Neurosci 18:7084-7098.
81. Takemori AE, Larson DL, Portoghese PS (1981) The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur J Pharmacol 70:445-451.
82. Tariot PN, Sunderland T, Murphy DL, Cohen MR, Welkowitz JA, Weingartner H, Newhouse PA, Cohen RM (1986) Design and interpretation of opiate antagonist trials in dementia. Prog Neuropsychopharmacol Biol Psychiatry 10:611-626.
83. Tortella FC, Robles L, Mosberg HI (1987) Evidence for μ opioid receptor mediation of enkephalin-induced electroencephalographic seizures. J Pharmacol Exp Ther 240:571-577.
84. von Zastrow M, Svingos A, Haberstock-Debic H, Evans C (2003) Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs. Curr Opin Neurobiol 13:348-353.
85. Whishaw IQ, Cassel JC, Jarrad LE (1995) Rats with fimbria-fornix lesions display a place response in a swimming pool: a dissociation between getting there and knowing where. J Neurosci 15:5779-5788.
86. Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M (2005) Familial Alzheimer's disease mutations inhibit γ-secretase-mediated liberation of β-amyloid precursor protein carboxy-terminal fragment. J Neurochem 94:1189-1201.
87. Williams JT, Christie MJ, Manzoni O (2001) Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81:299-343.
88. Williams SH, Johnston D (1996) Actions of endogenous opioids on NMDA receptor-independent long-term potentiation in area CA3 of the hippocampus. J Neurosci 16:3652-3660.